DailyIQ
|
Sector:HealthcareAll sectors
Last updated1 minute ago

ARGX·Argenx SE American Depositary Shares

$987.53
-2.79 (-0.28%)
After Hours
High
$1,001.95
Open
$996.50
Market Cap
54.30B
52W High
$1,074.70
Low
$986.56
P. Close
$987.53
P/E
25.19
52W Low
$661.56
Fwd P/E
28.53
DailyIQ Est.
$1242.11
Inst. Ownership
30.4%
Short Interest
2.29%
Days to Cover
3.9
Technical Score (1D)
50
NEUTRAL
News Sentiment
50
MIXED
ARGX’s ADR has just entered a Stage 2 uptrend and now satisfies Minervini’s Trend Template, a technical signal that the stock is gaining relative strength within its sector. The underlying driver is the company’s robust EPS and revenue growth, which has been consistently outpacing peers and supports the bullish momentum. Because the technical breakout aligns with solid fundamentals, the market may view ARGX as a stronger play for the next 1–10 trading days, potentially attracting momentum‑driven traders. The lack of new catalysts or earnings guidance in the report means the current valuation remains unchanged, but the technical confirmation could prompt a short‑term rally. Watch for the next resistance level around the recent high; a break above could validate the trend and push the price higher. Conversely, a pullback to the previous support could signal a temporary correction. Monitor the company’s upcoming earnings release for any guidance that could either reinforce or undermine the current bullish narrative. Finally, keep an eye on sector‑wide sentiment, as any shift in the broader biotech landscape could quickly alter ARGX’s relative strength.
Earnings Summary
argenx SE is a commercial‑stage biotechnology company focused on autoimmune therapies, with its flagship product VYGART approved for generalized myasthenia gravis and a growing pipeline of investigational candidates. In Q4 2024, the company reported EPS of $0.71 versus an estimate of $1.70, while revenue of $724.4 million matched expectations, indicating a significant EPS miss despite stable top line. The earnings data for 2026 are incomplete, with no EPS reported for Q2 2026 and Q3 2026, but revenue estimates of $1.567 billion and $1.679 billion suggest a potential upside in top‑line growth once the company reports results. Historically, argenx has experienced volatile earnings, with large swings between positive and negative guidance, reflecting the inherent risk of clinical development and regulatory milestones. Recent news highlights the company’s presentation at the Morgan Stanley Global Healthcare Conference, where it reiterated progress on its pipeline and partnership prospects, and a modest decline in ADRs driven by broader European biotech sentiment rather than company‑specific events. Investors should watch for the upcoming earnings release for updated sales guidance, clinical data, and any partnership announcements, as these will be key determinants of the company’s valuation and future growth prospects.

EPS

EstBeatMiss
$-0.22$1.80$3.83$5.85$7.88Q4'24Q2'26
QtrEstActual+/−
Q2'26$6.94 - -
Q4'24$1.70$0.71-58.0%

Revenue

EstBeatMiss
$598M$872M$1.1B$1.4B$1.7BQ4'24Q2'26
QtrEstActual+/−
Q2'26$1.6B - -
Q4'24 - $724M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ARGX Stock Snapshot

HOLD50/100
$988.20+$0.67 (0.1%)
Market cap
54.30B
P/E ratio
25.2
Day range
$986.56 – $1001.95
News sentiment
50/100 · Neutral
Analyst target
$1180.61 (+19.5%)
Consensus
Buy · 27 analysts
52-week range+49.4% off low · -8.0% from high
$661.56$1074.70
Price $988.20 DailyIQ Est. $1242.11

Momentum has flattened on ARGX, leaving the next move dependent on news rather than the chart. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Sector Rotation

Is money rotating into or out of ARGX's sector?

Argenx SE American Depositary Shares sits in the Health Care sector, currently ranked 5th of 11 GICS sectors by relative-strength rotation score (improving). Within its narrower Retail industry group, ARGX ranks 9th of 15 tracked industries, lagging.

Sector rank
#5 of 11
Sector state
Improving
Sector rotation score
80
Industry rank
#9 of 15

Options Market

What is the options market pricing for ARGX?

CallsPuts

For Argenx SE American Depositary Shares's nearest expiry (2026-10-16, 25 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.23), with at-the-money implied volatility around 38.0%. The options market is pricing roughly a ±9.6% move by that expiry — a range of about $895.30–$1085.34.

Put/call ratio (2026-10-16)
0.23
ATM implied volatility
38.0%
Total open interest
1,289
Expected move by 2026-10-16
±9.6% ($895.30–$1085.34)

Analyst Rating Changes

Are analysts turning bullish or bearish on ARGX?

Wedbush most recently reiterated its rating on Argenx SE American Depositary Shares to Outperform on Sep 8, 2026 with a price target of $1150. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Wedbush — Outperform
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Sep 8, 2026WedbushReiteratedOutperform$1150
Sep 3, 2026WedbushReiteratedOutperform$1150
Aug 31, 2026Morgan StanleyMaintainedOverweight$1230 → $1250
Aug 26, 2026UBSUpgradeNeutral → Buy$960 → $1400
Aug 26, 2026Wells FargoMaintainedOverweight$1350 → $1415
Aug 18, 2026Truist SecuritiesMaintainedBuy$1030 → $1095
Aug 18, 2026Morgan StanleyMaintainedOverweight$1200 → $1230
Aug 18, 2026RBC CapitalMaintainedOutperform$1025 → $1100
Aug 18, 2026CitizensMaintainedMarket Outperform$932 → $1200
Aug 18, 2026WedbushMaintainedOutperform$1050 → $1150
Aug 18, 2026HC Wainwright & Co.MaintainedBuy$940 → $1202
Aug 17, 2026Piper SandlerMaintainedOverweight$1075 → $1215

ARGX Competitive Positioning

Argenx SE American Depositary Shares (ARGX) is tracked alongside these names in Biotechnology on DailyIQ — ranked by market cap, with today's move alongside.

Held by These ETFs

ARGX is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.